The "research use only" designation is a regulatory category, not a marketing phrase, and material sold under that designation is not intended for, and is not lawful for, human or animal administration [6][14]
Co-administration is pharmacologically contradictory and should be avoided
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
The flux into the glutathione pathway (CBS) does not vary very much between males and females
Iron deficiency anemia and levels of oxidative stress induced by treatment modality: Iron deficiency anemia and oxidative stress
Combines with dietary improvement in DIO mice to accelerate weight/fat loss and improve composition versus diet alone [3,4]